Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Delayed Swiss Exchange  -  11:31:24 2023-01-27 am EST
531.20 CHF   +0.04%
01/27Intron Health Lowers Price Target on Lonza Group, Maintains Hold Recommendation
MT
01/25Lonza Group AG Provides Earnings Guidance for the Year 2023
CI
01/25Lonza Group Seeks Mergers and Acquisitions
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil

03/21/2022 | 01:08am EST
  • Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
  • The collaboration is projected to take Cantrixil through the planned Phase II clinical trial
  • Manufacturing to begin in March 2022 at Lonza's HPAPI manufacturing laboratories in Nansha, China

Solna, Sweden and Basel, Switzerland, 21 March 2022 - Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, announced today that the companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of clinical material for its investigational drug candidate, Cantrixil.

Cantrixil, an intraperitoneally administered drug in development for the treatment of late-stage ovarian cancer, was licensed by Oasmia from the Australian pharmaceutical company Kazia in 2021, having successfully completed a Phase I trial. Ovarian cancer is one of the most aggressive cancers and is difficult to treat in advanced stages. The Phase I study of Cantrixil demonstrated the potential for it to provide prolonged survival in advanced ovarian cancer by inducing ovarian cancer stem cells' death and sensitizing cancer cells to standard chemotherapy. Oasmia is now preparing for the initiation of a Phase II trial of Cantrixil in advanced ovarian cancer.

Under the terms of the agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza's extensive experience and expertise in manufacturing highly-potent API (HPAPI). The drug substance will be manufactured at Lonza's recently expanded production facility at Nansha, China. Manufacturing is expected to begin in March 2022.

Kai Wilkinson, Chief Technical Officer at Oasmia, commented:"We are excited to have partnered with Lonza, a global leader in drug manufacturing. The manufacture of Cantrixil is planned to be performed in three steps and this agreement is the first and most crucial step in us securing the clinical drug supply for its development."Christian Dowdeswell, VP and Global Head, Commercial Development - Small Molecules, Lonza, added: "Our team has extensive experience supporting the development and manufacture of challenging molecules. We are looking forward to collaborating with Oasmia to advance this promising drug candidate in the clinic."

Disclaimer

Lonza Group Ltd. published this content on 21 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 March 2022 06:07:05 UTC.


ę Publicnow 2022
All news about LONZA GROUP AG
01/27Intron Health Lowers Price Target on Lonza Group, Maintains Hold Recommendation
MT
01/25Lonza Group AG Provides Earnings Guidance for the Year 2023
CI
01/25Lonza Group Seeks Mergers and Acquisitions
CI
01/25Transcript : Lonza Group AG, 2022 Earnings Call, Jan 25, 2023
CI
01/25Lonza Sweetens Shareholder Returns After COVID-19-related Sales Peak Drives 2022 Result..
MT
01/25Lonza Shares Fall But Regain Ground Following 2022 Result
DJ
01/25European shares slip as investors weigh earnings reports
RE
01/25Lonza's 2022 Core Earnings and Sales Increased; Plans a Share Buyback
DJ
01/25Lonza Group Profit Balloons 80% in 2022 Amid 15% Increase in Sales
MT
01/25Lonza underscores growth prospects with share buy-back, dividend hike
RE
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2023 6 767 M 7 347 M 7 347 M
Net income 2023 1 124 M 1 221 M 1 221 M
Net Debt 2023 859 M 933 M 933 M
P/E ratio 2023 34,3x
Yield 2023 0,67%
Capitalization 39 409 M 42 787 M 42 787 M
EV / Sales 2023 5,95x
EV / Sales 2024 5,29x
Nbr of Employees 17 154
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 531,20 CHF
Average target price 664,65 CHF
Spread / Average Target 25,1%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Maria Soler Nunez Head-Group Operations
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG17.24%42 787
MODERNA, INC.7.58%72 745
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117
CELLTRION, INC.3.93%19 410